GlassScriptPhysician profile
Caitlyn Grace Kay
NPI 1629833835
$2,985.88
in general payments reported to CMS, 2019-2025
21 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,178 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,985.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $627.78 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $509.15 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $265.39 | 2024-2025 | Unithroid |
| Medtronic, INC. | $238.32 | 2024-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $213.01 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $168.56 | 2024-2025 | |
| Insulet Corporation | $151.56 | 2024-2025 | Omnipod |
| Madrigal Pharmaceuticals | $120.90 | 2024 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.95 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $72.73 | 2024-2025 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $65.65 | 2024-2025 | |
| Corcept Therapeutics | $61.11 | 2024-2025 | Korlym |
| Amgen INC. | $60.56 | 2025 | Tepezza |
| Xeris Pharmaceuticals, INC. | $58.67 | 2024-2025 | Gvoke Hypopen, Recorlev |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $46.89 | 2024-2025 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $39.20 | 2024 | Farxiga |
| Dexcom, INC. | $35.39 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $29.97 | 2025 | Veozah |
| Radius Health, INC. | $21.24 | 2025 | |
| Recordati_rare_diseases_inc. | $16.86 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlyn Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.